Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
FILPEGLA (Cipla Australia Pty Ltd)
Product name
FILPEGLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
Pegfilgrastim
Registration type
NCE/NBE
Indication
FILPEGLA is indicated for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and so reduce the incidence of infection, as manifested by febrile neutropenia.